[Form 4] Nurix Therapeutics, Inc. Common stock Insider Trading Activity

Rhea-AI Filing Summary

On 07/30/2025 director Harpreet Saluja filed a Form 4 for Primoris Services Corp. (PRIM).

• Transaction: Automatic acquisition (code “A”) of 499 restricted common shares under the company’s non-employee director compensation plan.
• Value basis: Grant amount reflects program formula of $37,500, converted to shares using the average closing price for June 2025 (share-price not disclosed in the filing).
• Holding terms: Shares are subject to a 12-month sale restriction; reporting person’s ownership after the grant totals 499 direct shares.
• Purpose: Routine annual equity compensation; no open-market purchase or sale was reported and no derivatives were involved.

The filing does not disclose any changes to overall share count, guidance, or financial performance and therefore appears immaterial to PRIM’s near-term valuation.

Insights

Corporate Governance Expert

TL;DR: Routine director equity grant; negligible market impact.

This Form 4 documents a standard non-employee director stock award—499 restricted shares valued at $37,500. Such grants align director incentives with shareholder interests but are quantitatively immaterial relative to PRIM’s float and market cap. There are no derivative positions, insider sales, or changes suggesting shifting sentiment. Restrictions prevent resale for one year, further reducing any immediate trading effect. In governance terms, the filing demonstrates ongoing compliance with the 2011 compensation program, updated 2024. From a portfolio perspective, the event is neutral and does not warrant action.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hansen Gwenn

(Last) (First) (Middle)

C/O NURIX THERAPEUTICS, INC.

1700 OWENS STREET, SUITE 205

(Street)

SAN FRANCISCO CA 94158

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nurix Therapeutics, Inc. [ NRIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
07/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/30/2025		M		3,207	A	$0	64,723	D
Common Stock	07/30/2025		M		2,000	A	$0	66,723	D
Common Stock	07/30/2025		M		3,750	A	$0	70,473	D
Common Stock	07/30/2025		M		2,858	A	$0	73,331	D
Common Stock	07/30/2025		S(1)		4,308	D	$12.011(2)	69,023	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0(3)	07/30/2025		M			3,207	(4)	(5)	Common Stock	3,207	$0	6,414	D
Restricted Stock Units	$0(3)	07/30/2025		M			2,000	(6)	(5)	Common Stock	2,000	$0	6,000	D
Restricted Stock Units	$0(3)	07/30/2025		M			3,750	(7)	(5)	Common Stock	3,750	$0	26,250	D
Restricted Stock Units	$0(3)	07/30/2025		M			2,858	(8)	(5)	Common Stock	2,858	$0	31,442	D

Explanation of Responses:

1. The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

2. Represents the weighted average sale price. The lowest price at which shares were sold was $11.78 and the highest price at which shares were sold was $12.315. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

3. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

4. The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.

5. RSUs do not expire; they either vest or are canceled prior to the vest date.

6. The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.

7. The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.

8. The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2025, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.

Remarks:

	/s/ Daniel Burbach, as Attorney-in-Fact for Gwenn Hansen	07/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Primoris Services (PRIM) shares did director Harpreet Saluja receive?

499 restricted common shares were granted on 07/30/2025.

What is the dollar value of the PRIM stock grant reported in the Form 4?

The compensation program sets the value at $37,500, converted to shares using June 2025’s average closing price.

Are the newly granted PRIM shares immediately tradable?

No. The shares cannot be sold for 12 months from the grant date.

Does the filing involve any derivative securities or insider sales?

No derivative positions or sales were reported—only the restricted stock grant.

Is this Form 4 likely to impact PRIM’s stock price?

The grant is routine and immaterial; it is unlikely to affect trading dynamics.